Evaluation of serum Midkine as a Diagnostic Marker for Hepatocellular Carcinoma in Hepatitis C virus Patients with Liver Cirrhosis
Sheata, M., ElFakhry, A., El Torgoman, A., El-Ghlban, S. (2022). Evaluation of serum Midkine as a Diagnostic Marker for Hepatocellular Carcinoma in Hepatitis C virus Patients with Liver Cirrhosis. EKB Journal Management System, 65(3), 637-645. doi: 10.21608/ejchem.2021.84948.4140
Mohammed Kamel Sheata; Ashraf Abdel-Megid ElFakhry; Abdel Moneim El Torgoman; Samah El-Ghlban. "Evaluation of serum Midkine as a Diagnostic Marker for Hepatocellular Carcinoma in Hepatitis C virus Patients with Liver Cirrhosis". EKB Journal Management System, 65, 3, 2022, 637-645. doi: 10.21608/ejchem.2021.84948.4140
Sheata, M., ElFakhry, A., El Torgoman, A., El-Ghlban, S. (2022). 'Evaluation of serum Midkine as a Diagnostic Marker for Hepatocellular Carcinoma in Hepatitis C virus Patients with Liver Cirrhosis', EKB Journal Management System, 65(3), pp. 637-645. doi: 10.21608/ejchem.2021.84948.4140
Sheata, M., ElFakhry, A., El Torgoman, A., El-Ghlban, S. Evaluation of serum Midkine as a Diagnostic Marker for Hepatocellular Carcinoma in Hepatitis C virus Patients with Liver Cirrhosis. EKB Journal Management System, 2022; 65(3): 637-645. doi: 10.21608/ejchem.2021.84948.4140

Evaluation of serum Midkine as a Diagnostic Marker for Hepatocellular Carcinoma in Hepatitis C virus Patients with Liver Cirrhosis

Egyptian Journal of Chemistry
Article 60, Volume 65, Issue 3, March 2022, Page 637-645  XML PDF (389.48 K)
Document Type: Original Article
DOI: 10.21608/ejchem.2021.84948.4140
View on SCiNiTO View on SCiNiTO
Authors
Mohammed Kamel Sheata1; Ashraf Abdel-Megid ElFakhry2; Abdel Moneim El Torgoman3; Samah El-Ghlban email orcid 4
1Biochemistry Division, Department of chemistry, Faculty of science, Mansoura University, Egypt
2Department of Internal Mediciene, Faculty of Medicine, Mansoura university, Egypt
3Department of Organic Chemistry , Faculty of science, Menofia university, Egypt
4Biochemistry Division, Chemistry Department, Faculty of science, Menofia university, Egypt
Abstract
Background: Hepatocellular carcinoma (HCC) is the commonest primary malignant cancer of the liver and the sixth most common cancer in the world. Its incidence is increasing worldwide reaching half million cases each year. The primary marker for HCC is Alpha Feto Protein (AFP) which is not secreted in all cases of HCC and may be normal in as many as 40% of patients with early HCC. Midkine(MK) is a heparin-binding cytokine or growth factor, promoting survival, growth, migration, gene expression and other activities of target cells. MK is over expressed in hepatocellular carcinoma.
Objectives: The aim of the study is to evaluate the diagnostic value of MK as a tumor marker of HCC.
Patients and Methods: This study was conducted on 85 patients who were classified into three groups: Group I (HCC) group included 45 patients with HCC. Group II (Liver cirrhosis) group included 30 patients without any evidence of hepatic focal lesions as excluded by ultrasonography and AFP estimation. Group III (control group) included 10 normal people. The level of AFP and MK were estimated for all cases together with full clinical assessment liver biochemical profile, viral markers, conventional US and triphasic abdominal CT for HCC cases.
Results: Serum AFP median level was significantly (P
Keywords
Keywords: Alfpha feto protein; Inflammation; Hepatitis-B
Statistics
Article View: 388
PDF Download: 126